Literature DB >> 8175027

What is a normal CA125 level?

T Alagoz1, R E Buller, M Berman, B Anderson, A Manetta, P DiSaia.   

Abstract

CA125 is a coelomic epithelial antigen which is widely used to monitor residual disease in patients undergoing chemotherapy for ovarian cancer. Interpretation of serum CA125 levels has been based on a normal value of 35 U/ml which was derived by screening a young, general population of blood donors which included women with intact reproductive systems. This study addresses the issue of what constitutes a normal serum CA125 level following successful surgical therapy for gynecologic malignancy. Three hundred ninety-three CA125 values were measured in 145 patients after an elapsed time of at least 1 year following completion of surgical therapy for early-stage endometrial or cervical adenocarcinoma. All patients were without evidence of recurrent disease. The mean duration of followup was 4.3 years with a median of 3.7 years. Sixty-seven percent of the CA125 values were less than 10 U/ml; 95% were less than or equal to 20 U/ml. The median value for this patient population was 7.5 U/ml with a mode of 7.1 U/ml. There was no correlation between patient age and CA125 levels. These data suggest that the normal value for CA125 used for patient follow-up after treatment for gynecologic adenocarcinoma needs to be redefined. Our data support an upper limit of normal of 20 U/ml and encourage further study on the clinical impact of this new definition.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8175027     DOI: 10.1006/gyno.1994.1093

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Role of spiral artery Doppler to screen type 2 endometrial cancer cases.

Authors:  Soner Düzgüner; Mehmet Burak Ozkan; Tuncay Küçüközkan; Enis Ozkaya; Fadıl Kara; Ipek Nur Balın; Vakkas Korkmaz; Mehmet Fatih Karslı; Burak Gültekin
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-03-01

Review 2.  Current state of biomarker development for clinical application in epithelial ovarian cancer.

Authors:  Richard G Moore; Shannon MacLaughlan; Robert C Bast
Journal:  Gynecol Oncol       Date:  2009-10-31       Impact factor: 5.482

3.  Premenopausal early-stage endometrial carcinoma patients with low CA-125 levels and low tumor grade may undergo ovary-saving surgery.

Authors:  Seung-Chul Yoo; Jong-Hyuck Yoon; Woo Young Kim; Suk-Joon Chang; Hee-Jae Joo; Ki-Hong Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2009-09-30       Impact factor: 4.401

4.  The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients.

Authors:  Beyhan Omer; Sema Genc; Ozguc Takmaz; Ahmet Dirican; Zeynep Kusku-Kiraz; Sinan Berkman; Figen Gurdol
Journal:  Tumour Biol       Date:  2013-05-03

5.  Utility of Preoperative CA125 Assay in the Management Planning of Women Diagnosed with Uterine Cancer.

Authors:  N Povolotskaya; N Das; K Dhar; D Brinkmann; F Gardner; R Woolas
Journal:  Surg Res Pract       Date:  2014-02-27

6.  Cancer antigen 125 is associated with disease status in uterine carcinosarcoma.

Authors:  Malcolm Strachan Ross; Chelsea Kilpatrick Chandler; Koji Matsuo; John Austin Vargo; Esther Elishaev; Nalyn Siripong; Jessica Layne Berger; Joseph Leo Kelley; Sarah Elizabeth Taylor
Journal:  Rare Tumors       Date:  2019-11-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.